Abstract
Utilizing the co-transfection assay as a guide to determining structure activity relationships, we have been pursuing the discovery of non-steroidal hPR modulators. Small molecule, non-steroidal lead structures have been identified. Optimization of these structures has yielded more potent hPR modulators. Improved cross-reactivity profiles with other intracellular receptors are a feature of these compounds owing to their non-steroidal nature.
MeSH terms
-
Animals
-
Anisoles / chemistry
-
Anisoles / pharmacokinetics
-
Chlorocebus aethiops
-
Chlorophyta / chemistry
-
Cyclohexanes / chemistry
-
Cyclohexanes / pharmacokinetics
-
Drug Design*
-
Estrogen Replacement Therapy
-
Female
-
Gonanes / chemistry
-
Gonanes / pharmacokinetics
-
Hormone Antagonists / chemistry*
-
Hormone Antagonists / pharmacokinetics
-
Humans
-
Mifepristone / chemistry
-
Mifepristone / pharmacokinetics
-
Molecular Structure
-
Progesterone Congeners / adverse effects*
-
Progesterone Congeners / pharmacokinetics
-
Receptors, GABA / drug effects
-
Receptors, GABA / physiology
-
Receptors, Progesterone / drug effects*
-
Receptors, Progesterone / metabolism
-
Receptors, Steroid / drug effects
-
Receptors, Steroid / metabolism
-
Recombinant Proteins / drug effects
-
Sleep Stages / drug effects
-
Structure-Activity Relationship
-
Transfection
Substances
-
Anisoles
-
Cyclohexanes
-
Gonanes
-
Hormone Antagonists
-
LG 100127
-
Progesterone Congeners
-
Receptors, GABA
-
Receptors, Progesterone
-
Receptors, Steroid
-
Recombinant Proteins
-
Mifepristone
-
onapristone